Back
Corporate News
Wanbury Limited receives FDA approval for Metformin HCl API ANDAs
30-Jul-2026, 11:00
Wanbury Limited announced on July 30, 2026, that it received a “No DMF deficiency letter” from the U.S. Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs) related to Metformin HCl API sourced from Wanbury.
Wanbury Limited announced on July 30, 2026, that it received a “No DMF deficiency letter” from the U.S. Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs) related to Metformin HCl API sourced from Wanbury.